Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9522944 | 0.75 | MEN1 (0.43) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL11920854 | 0.75 | KMT2A (0.46) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL9673263 | 0.72 | MEN1 (0.53) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL13529459 | 0.71 | MEN1 (0.41) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL24553986 | 0.71 | MEN1 (0.47) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL13439389 | 0.71 | MEN1 (0.45) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL23116096 | 0.70 | MEN1 (0.44) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL11024894 | 0.70 | MEN1 (0.54) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL6708639 | 0.69 | MEN1 (0.46) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL16376197 | 0.68 | MEN1 (0.56) | L3MBTL1MEN1KMT2AKDM4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | L3MBTL1 4625/4885MEN1 4009/4885KMT2A 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.